Clinicohematological features and characteristics of the mutated genes of epigenetic modifiers and their coexisted mutations in 10 pediatric AML patients
| Patient no. . | Age, y/sex . | FAB . | Cytogenetics/genetic subclass . | Mutated gene . | Amino acid change . | Cooperative mutations . | Treatment protocol . | Event-free survival, mo . |
|---|---|---|---|---|---|---|---|---|
| 157 | 10/M | M2 | 45×,-Y,t(8;21) | ASXL1 | P835DfsX7 | Nil | 97A | 68+ |
| 171 | 2/F | M2 | 46XX,t(8;12;21) | ASXL1 | E635RfsX15 | Nil | 97A | 17 |
| 64 | 5/F | M0 | 47XX,+ 21 | IDH1 | R132C | MLL-PTD | 97B | 14 |
| RUNX1 (V333Dfs*242) | ||||||||
| 132 | 11/M | M0 | 46XY | IDH1 | R132H | FLT3-ITD | 97A | 87+ |
| MLL-PTD | ||||||||
| 111 | 10/M | M2 | 46XY | IDH2 | R140Q | FLT3-ITD | 97B | 110+ |
| NPM1 (type D) | ||||||||
| 127 | 11/M | M5 | 48XY,+11,+20 | DNMT3A | R882H | PTPN11 (E76K) | 97A | 93+ |
| 197 | 14/M | M4 | 46XY,MLL translocation | DNMT3A | W795S | FLT3-TKD (D835E) | 97A | 10 |
| WT1 (A382Gfs*3) | ||||||||
| 28 | 13/M | M2 | 45×,-Y,t(8;21) | TET2 | E1364* | FLT3-TKD (D835V) | 97B | 0 |
| 36 | 14/M | M1 | 46XY | TET2 | R1359C | FLT3- ITD, CEBPα [P46H fs*115 (;) K304_Q305 insL] | 97B | 167+ |
| 160 | 16/M | M2 | 45×,-Y,t(8;21) | TET2 | F760Y | KRAS (G13R), WT1 (R434Hfs*86) | 97B | 8.9 |
| Patient no. . | Age, y/sex . | FAB . | Cytogenetics/genetic subclass . | Mutated gene . | Amino acid change . | Cooperative mutations . | Treatment protocol . | Event-free survival, mo . |
|---|---|---|---|---|---|---|---|---|
| 157 | 10/M | M2 | 45×,-Y,t(8;21) | ASXL1 | P835DfsX7 | Nil | 97A | 68+ |
| 171 | 2/F | M2 | 46XX,t(8;12;21) | ASXL1 | E635RfsX15 | Nil | 97A | 17 |
| 64 | 5/F | M0 | 47XX,+ 21 | IDH1 | R132C | MLL-PTD | 97B | 14 |
| RUNX1 (V333Dfs*242) | ||||||||
| 132 | 11/M | M0 | 46XY | IDH1 | R132H | FLT3-ITD | 97A | 87+ |
| MLL-PTD | ||||||||
| 111 | 10/M | M2 | 46XY | IDH2 | R140Q | FLT3-ITD | 97B | 110+ |
| NPM1 (type D) | ||||||||
| 127 | 11/M | M5 | 48XY,+11,+20 | DNMT3A | R882H | PTPN11 (E76K) | 97A | 93+ |
| 197 | 14/M | M4 | 46XY,MLL translocation | DNMT3A | W795S | FLT3-TKD (D835E) | 97A | 10 |
| WT1 (A382Gfs*3) | ||||||||
| 28 | 13/M | M2 | 45×,-Y,t(8;21) | TET2 | E1364* | FLT3-TKD (D835V) | 97B | 0 |
| 36 | 14/M | M1 | 46XY | TET2 | R1359C | FLT3- ITD, CEBPα [P46H fs*115 (;) K304_Q305 insL] | 97B | 167+ |
| 160 | 16/M | M2 | 45×,-Y,t(8;21) | TET2 | F760Y | KRAS (G13R), WT1 (R434Hfs*86) | 97B | 8.9 |
AML indicates acute myeloid leukemia; FAB, French-American-British classification; ITD, internal tandem duplication; PTD, partial tandem duplication of MLL; and TKD, tyrosine kinase domain.